CRISPR Therapeutics reported Q3 2024 financial results with a strong cash position of $1.94 billion as of September 30, 2024. The company's flagship product CASGEVY received additional approvals in Switzerland and Canada for treating sickle cell disease and transfusion-dependent beta thalassemia in patients 12 years and older. As of mid-October, 45 authorized treatment centers have been activated globally with approximately 40 patients having completed cell collection.The company's clinical pipeline continues to advance, with promising preliminary data from CTX112, their next-generation CD19 CAR-T therapy, showing a 67% overall response rate in lymphoma patients. Two clinical trials are ongoing for CTX131 targeting CD70 in solid tumors and hematological malignancies. Additionally, in vivo programs CTX310 and CTX320 for cardiovascular diseases are progressing in clinical trials.Q3 financial results showed R&D expenses of $82.2 million, down from $90.7 million year-over-year, and a net loss of $85.9 million compared to $112.2 million in Q3 2023. The company's strong balance sheet was bolstered by a $280 million offering and a $200 million milestone payment from Vertex Pharmaceuticals following CASGEVY's approval.

CRISPR Therapeutics reported Q3 2024 financial results with a strong cash position of $1.94 billion as of September 30, 2024. The company's flagship product CASGEVY received additional approvals in Switzerland and Canada for treating sickle cell disease and transfusion-dependent beta thalassemia in patients 12 years and older. As of mid-October, 45 authorized treatment centers have been activated globally with approximately 40 patients having completed cell collection.The company's clinical pipeline continues to advance, with promising preliminary data from CTX112, their next-generation CD19 CAR-T therapy, showing a 67% overall response rate in lymphoma patients. Two clinical trials are ongoing for CTX131 targeting CD70 in solid tumors and hematological malignancies. Additionally, in vivo programs CTX310 and CTX320 for cardiovascular diseases are progressing in clinical trials.Q3 financial results showed R&D expenses of $82.2 million, down from $90.7 million year-over-year, and a net loss of $85.9 million compared to $112.2 million in Q3 2023. The company's strong balance sheet was bolstered by a $280 million offering and a $200 million milestone payment from Vertex Pharmaceuticals following CASGEVY's approval.